Acasti Pharma Inc.

Acasti Pharma granted allowance for patents in 3 more countries for drug candidate Capre

Acasti Pharma (NASDAQ: ACST-CVE:ACST) Co-Founder and Chief Operating Officer Pierre Lemieux joined Steve Darling from Proactive Investors Vancouver to bring news Acasti received 3 new patents for their flagship drug candidate CaPre.

Lemieux talks about what this means for the company going forward and where in the pipeline CaPre is and what trials will happen this year.

Quick facts: Acasti Pharma Inc.

Price: $2.54

Market: TSX-V
Market Cap: $215.44 m


Acasti Pharma eyes phase III success with double data readout towards year-end

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) CEO Jan D'Alvise speaks to Proactive's Andrew Scott after announcing their second Phase III trial for the drug CaPre has reached 100% randomisation - which means the last patient's been accepted into the trial and randomised either onto the drug or a...

on 4/6/19

2 min read